Key highlights
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 30 Press Releases
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
PARIS, FRANCE, 22 February 2023 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
PARIS, FRANCE, MONTREAL, CANADA 15 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncolog
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
CORRECTED and REPLACING: Minor updates were made on 24 April 2023 to correct an error in the original data analysis impacting the blinded independent central reviewer (BICR)-assessed data points (PFS, ORR, and DoR). The safety and efficacy profile, includi
Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
Ioana Piscociu
Senior Manager, Media Relations
Related links